marin
spong
phylum
porifera
among
oldest
multicellular
invertebr
organ
exhibit
wide
varieti
color
shape
speci
spong
inhabit
differ
marin
freshwat
ecosystem
describ
date
marin
spong
rich
sourc
potent
natur
product
consid
highli
signific
lead
compound
drug
develop
secondari
metabolit
produc
spong
may
produc
defend
pathogen
bacteria
alga
fungi
potenti
predat
system
develop
process
evolut
throughout
thousand
year
differ
natur
compound
discov
spong
associ
microorgan
everi
year
sever
hundr
new
compound
ad
antivir
compound
current
particular
interest
sinc
viral
diseas
eg
hiv
hsv
etc
becom
major
human
health
problem
recent
decad
abil
viru
rapidli
evolv
develop
resist
exist
pharmaceut
call
continu
develop
new
antivir
drug
sever
lead
antivir
compound
isol
marin
spong
consist
effort
identifi
new
compound
nucleosid
spongothymidin
spongouridin
first
compound
isol
marin
spong
tethya
crypta
led
synthesi
arac
anticanc
agent
araa
first
antivir
drug
araa
inhibit
viral
dna
synthesi
convers
adenin
arabinosid
triphosph
inhibit
viral
dna
polymeras
dna
synthesi
herp
vaccinica
varicella
zoster
virus
use
clinic
treatment
herp
viru
infect
araa
spong
deriv
compound
approv
us
fda
antivir
drug
although
market
later
stop
found
less
effici
toxic
newer
drug
acyclovir
zovirax
addit
nucleosid
marin
spong
also
sourc
mani
alkaloid
sterol
terpen
peptid
fatti
acid
peroxid
etc
exhibit
remark
chemic
divers
compound
found
organ
sever
spong
deriv
antivir
compound
preclinicalclin
trial
variou
diseas
howev
signific
problem
associ
compound
major
limit
drug
develop
approv
process
primarili
due
mani
technolog
challeng
detect
isol
character
scale
product
bioactiv
compound
marin
spong
solv
critic
suppli
problem
sever
effort
made
spong
farm
metagenom
microbi
cultiv
discuss
focu
exist
promis
antivir
lead
compound
marin
spong
may
potenti
futur
drug
bergmann
et
al
isol
caribbean
spong
tethya
crypta
tethylida
nucleosid
spongothymidin
spongouridin
contain
arabinos
sugar
rather
common
ribos
sugar
found
nucleosid
vidarabin
araa
synthet
analogu
spongouridin
improv
antivir
activ
antivir
activ
adenin
arabinosid
vidarabin
araa
figur
first
describ
privat
de
garilh
de
rudder
work
whitley
confirm
clinic
use
compound
treatment
herp
enceph
herp
infect
occasion
occur
newborn
first
nucleosid
antivir
licens
treatment
systemat
herp
viru
infect
one
three
marinederiv
drug
current
approv
fda
unit
state
howev
market
drug
discontinu
avail
newer
better
antivir
agent
market
despit
proven
abil
therapeut
agent
activ
varieti
virus
vidarabin
signific
limit
readili
metabol
adenosin
deaminas
ada
arabinofuranosyl
hypoxanthin
arah
less
potent
low
lipophil
thu
low
intestin
membran
permeabl
also
poorli
solubl
aqueou
solut
low
intramuscular
absorpt
requir
larg
fluid
volum
intraven
administr
must
given
prolong
period
h
obtain
therapeut
effect
later
acyclovir
zovirax
found
better
drug
vidarabin
treatment
herp
viru
infect
howev
vidarabin
report
capabl
inhibit
acyclovirresist
hsv
vzv
varicellazost
viru
vidarabin
inhibitor
viral
dna
synthesi
adenin
arabinosid
vidarabin
convert
adenin
arabinosid
triphosph
araatp
vivo
kinas
encod
virus
turn
inhibit
viral
dna
polymeras
henc
dna
synthesi
herp
vaccinia
varicella
zoster
virus
anoth
studi
found
vidarabin
incorpor
rna
well
dna
lead
anoth
possibl
mechan
action
drug
observ
vidarabin
inhibit
initi
rna
polyadenyl
reaction
catalyz
chromatinbound
poli
polymeras
also
recent
report
vidarabin
fold
activ
plaqu
reduct
assay
vaccinia
cowpox
virus
cidofovir
vistid
stereocontrol
synthesi
vidarabin
sever
analoguesderiv
antivir
activ
describ
biosynthesi
streptomyc
antibioticu
also
report
perri
et
al
first
report
isol
vitro
antivir
activ
mycalamid
mycalamid
b
figur
new
zealand
spong
genu
mycal
respect
crude
extract
contain
mycalamid
found
activ
corona
viru
treatment
crude
extract
mgkg
mice
infect
viru
surviv
day
howev
mice
infect
viru
die
within
eight
day
mycalamid
also
inhibit
herp
simplex
type
polio
type
virus
concentr
ngdisc
mycalamid
b
found
potent
mycalamid
activ
concentr
ngdisc
examin
mechan
involv
action
compound
burr
clement
discov
inhibit
protein
synthesi
translat
rna
protein
cellfre
lysat
rabbit
reticulocyt
new
studi
also
describ
bind
mycalamid
e
site
larg
ribosom
subunit
haloarcula
marismortui
inhibit
protein
synthesi
properti
protein
synthesi
inhibit
may
attribut
biolog
activ
antivir
agent
sever
studi
regard
total
synthesi
mycalamid
publish
four
analogu
mycalamid
recent
report
bind
nucleoprotein
np
influenza
viru
inhibit
multipl
also
shown
experiment
compound
might
bind
ntermin
acid
region
np
mediat
nuclear
transport
np
bind
viral
rna
henc
may
inhibit
viral
replic
avarol
sesquiterpenoid
hydroquinon
rearrang
driman
skeleton
first
isol
marin
spong
disidea
avara
chemic
structur
avarol
figur
establish
standard
analyt
method
chemic
degrad
stereocontrol
total
synthesi
compound
show
dosedepend
inhibitori
effect
replic
etiolog
agent
acquir
immun
defici
syndrom
aid
human
tlymphotrop
retroviru
htlv
iii
lymphadenopathyassoci
viru
human
cell
vitro
concentr
studi
suggest
mechan
involv
block
express
gag
protein
htlviii
cell
viru
infect
henc
block
viral
replic
studi
date
back
show
antivir
effect
avarol
due
increas
intracellular
level
superoxid
radic
superoxid
dismutas
glutathion
peroxidas
effect
avarol
elucid
found
complet
block
synthesi
glutamin
transfer
trna
crucial
synthesi
viral
proteas
requir
viral
prolifer
import
biolog
target
inhibit
avarol
deriv
includ
revers
transcriptas
play
key
role
earli
stage
viral
infect
inhibit
cyclooxygenas
thu
reduc
level
leukotrien
prostaglandin
vitro
infect
monocyt
modul
express
gene
hivinfect
cell
antivir
activ
avaron
structur
similar
compound
also
marin
spong
disidea
avara
deriv
also
report
sever
new
deriv
avarol
show
antivir
activ
also
extract
red
sea
spong
dysidea
cinerea
first
enantioselect
total
synthesi
avarol
report
ling
et
al
anoth
attempt
primmorph
model
vitro
cultur
spong
cell
use
model
system
produc
avarol
laboratori
cell
cultur
gene
cluster
approach
use
sustain
product
avarol
also
review
antihiv
cytotox
cyclic
depsipeptid
papuamid
isol
spong
theonella
mirabili
theonella
swinhoei
collect
along
north
coast
papua
new
guinea
two
group
nation
cancer
institut
univers
british
columbia
independ
report
isol
papuamid
b
mirabili
papuamid
b
c
swinhoei
respect
figur
extens
nmr
analysi
confirm
presenc
differ
amino
acid
residu
includ
alanin
threonin
two
glycin
residu
homoprolin
nmethylthreonin
acid
amid
link
dienoic
acid
papuamid
b
evalu
antihiv
activ
cell
base
assay
cemss
tcell
cultur
found
highli
potent
effect
concentr
ngml
activ
compound
found
virtual
ident
detail
mechanist
studi
antihiv
activ
papuamid
b
perform
andjel
et
al
inhibit
viral
entri
cell
shown
independ
chemokin
coreceptor
key
protein
involv
process
viral
entri
target
fda
approv
inhibitor
process
mechan
direct
interact
papuamid
viru
propos
witha
membran
target
mechan
believ
respons
virucid
activ
compound
similar
type
mechan
propos
antifung
sterol
depend
lipopeptid
papuamid
b
also
inhibit
viral
entri
concentr
nm
propos
mechan
target
phosphatidylserin
phospholipid
present
viral
membran
papuamid
c
found
less
potent
inhibit
concentr
fold
higher
papuamid
b
recent
studi
xie
et
al
report
total
synthesi
papuamid
b
isol
microspinosamid
cyclic
depsipeptid
figur
indonesian
collect
spong
sidonop
microspinosa
report
microspinosamid
contain
amino
acid
residu
includ
alanin
tryptophan
arginin
threonin
aspart
valin
two
prolin
tertleucin
nmethylglutamin
cysteic
acid
new
residu
antihiv
activ
crude
extract
microspinosa
first
discov
nation
cancer
institut
primari
antihiv
screen
aqueou
organ
extract
microspinosa
exhibit
antihiv
activ
microspinosamid
also
evalu
antihiv
activ
cell
base
vitro
assay
found
effect
concentr
cemss
arget
cell
cyclic
depsipeptid
spong
antihiv
activ
also
report
isol
alkaloid
figur
marin
spong
aapto
sp
collect
abrolho
bahia
brazil
preliminari
activ
crude
extract
inhibit
replic
vero
cell
concentr
first
report
coutinho
et
al
anoth
studi
confirm
activ
even
potent
acyclovir
found
inhibit
vero
cell
even
h
infect
suggest
inhibit
initi
event
replic
appar
compound
could
inhibit
express
immediateearli
protein
regul
splice
termin
nuclear
export
viral
transcript
thu
prevent
viral
replic
synthet
transform
methylaaptamin
first
isol
nakamura
cowork
also
report
novel
deriv
isoaaptamin
also
display
potent
activ
cutignano
et
al
report
isol
new
bromoindol
alkaloid
dragmacidin
f
figur
marin
spong
genu
halicortex
collect
southern
coast
ustica
island
itali
compound
demonstr
vitro
antivir
activ
respect
henc
like
respons
antivir
properti
exhibit
halicortex
extract
compound
unpreced
carbon
skeleton
presum
deriv
biosynthet
dragmacidin
cycliz
partial
oxid
form
total
synthesi
dragmacidin
f
describ
garg
et
al
manzamin
figur
isol
haliclona
sp
found
water
near
okinawa
japan
sakai
higa
quest
find
antitumor
compound
marin
organ
manzamin
class
alkaloid
uniqu
complex
polycycl
ring
system
coupl
moieti
report
divers
rang
bioactiv
includ
antimicrobi
antiparasit
antipesticid
activ
aid
opportunist
infect
isol
manzamin
spong
pachypellina
sp
porifera
demospongia
petrosida
oceanapiida
collect
manado
bay
sulawesi
indonesia
also
describ
studi
report
first
anti
hsvii
activ
compound
minim
effect
concentr
isol
manzamin
also
report
speci
marin
spong
enantioselect
total
synthesi
manzamin
describ
humphrey
et
al
recent
studi
describ
isol
manzamin
undescrib
spong
genusacanthostrongylophora
manado
bay
indonesia
key
oral
intraven
pharmacokinet
properti
rat
also
report
studi
first
publish
inform
regard
pharmacokinet
properti
manzamin
indic
compound
low
metabol
clearanc
reason
long
pharmacokinet
halflif
good
absolut
oral
bioavail
make
promis
potenti
lead
preclin
assess
possibl
develop
studi
also
report
activ
manzamin
x
neokauluamin
respect
compound
figur
isol
marin
spong
hamigera
tarangaensi
famili
anchinoida
hen
chicken
island
new
zealand
show
vitro
viru
inhibit
herp
polio
viru
slight
cytotox
concentr
per
disk
synthes
hamigeran
b
report
sever
group
total
compound
offici
approv
clinic
use
treatment
variou
viral
ailment
least
half
use
treatment
hiv
infect
spongederiv
compound
also
screen
antihiv
activ
show
interest
potenti
import
field
led
discoveri
mani
compound
antihiv
activ
avarol
microspinosamid
papuamid
etc
although
mani
antivir
lead
compound
deriv
spong
none
yet
approv
drug
except
araa
longer
use
one
reason
difficulti
obtain
sustain
suppli
complex
molecul
preclin
clinic
trial
pharmaceut
interest
compound
found
spong
present
minut
amount
exampl
order
obtain
even
mg
halichondrin
potent
cytostat
polyketid
spong
origin
metric
ton
spong
lissodendoryx
sp
must
extract
addit
difficult
chemic
synthes
compound
due
highli
complex
structur
addit
long
drug
develop
process
make
problem
even
challeng
clear
larg
amount
biomass
marin
spong
harvest
natur
event
would
put
speci
risk
extinct
environment
friendli
econom
feasibl
strategi
clearli
need
maricultur
spong
larg
scale
product
compound
option
insuffici
knowledg
condit
specif
paramet
growth
cultiv
spong
laboratori
limit
factor
cultur
cell
primmorph
product
metabolit
may
feasibl
futur
present
techniqu
unabl
produc
larg
amount
biomass
grow
bodi
evid
suggest
marin
natur
product
may
product
bacteri
symbiont
spong
faulkner
group
demonstr
first
time
natur
product
spong
could
bacteri
origin
microorgan
associ
spong
character
differ
phyla
divers
biotechnolog
import
review
isol
cultiv
spongeassoci
microorgan
microbi
ferment
produc
bioactiv
natur
product
also
anoth
option
larg
scale
product
compound
interest
success
strategi
depend
mani
factor
major
spong
associ
microorgan
difficult
cultur
improv
cultur
spong
associ
microorgan
supplement
media
spong
extract
catalas
sodium
pyruv
report
proport
total
cultur
bacteria
remain
low
total
bacteria
could
cultur
spong
candidaspongia
flabel
rhopaloeid
odorabil
furthermor
microorgan
isol
spong
may
necessarili
produc
compound
due
requir
intermedi
compound
host
bacteria
also
stop
produc
compound
interest
certain
time
artifici
media
may
caus
number
genet
factor
link
lack
select
pressur
cultur
develop
success
spong
cultur
method
essenti
understand
biolog
natur
live
condit
spong
affect
growth
metabolit
product
variou
method
cultur
spong
spong
symbiont
review
previous
attempt
develop
grow
vitro
cell
line
spong
metabolit
product
also
report
metagenom
anoth
strategi
use
success
identifi
biosynthet
origin
natur
product
procedur
involv
genom
analysi
total
dna
organ
symbiont
past
year
metagenom
emerg
potenti
solut
genet
character
uncultur
bacteria
associ
marin
spong
method
involv
direct
extract
clone
dna
group
bacteria
genom
sequenc
initi
effort
includ
identif
isol
gene
cluster
respons
product
secondari
metabolit
involv
biosynthet
pathway
polyketid
synthas
pk
gene
cluster
anoth
studi
report
clone
chondramid
biosynthesi
cluster
c
crocatu
myxobacterium
metagenom
approach
also
employ
character
spongespecif
candid
phylum
poribacteria
new
molybdenumcontain
oxidoreductas
transmembran
protein
identifi
gene
cluster
identifi
use
metagenom
approach
step
forward
toward
solv
problem
mass
product
relev
natur
product
depend
express
isol
gene
cluster
relev
host
heterolog
express
vector
use
express
pk
biosynthet
cluster
pseudomona
putida
exampl
express
host
includ
e
coli
myxobacteria
streptomyc
use
express
variou
biosynthet
pathway
long
et
al
appli
express
base
techniqu
identifi
express
clone
isol
compound
marin
metagenom
success
limit
extent
technolog
effect
employ
soil
metagenom
sever
antibiot
isol
use
metagenom
approach
although
studi
demonstr
success
achiev
use
metagenom
approach
still
technolog
issu
relat
approach
must
overcom
studi
provid
compel
evid
natur
product
known
polyketid
structur
similar
spong
symbiont
bacteria
made
clear
bacteria
key
produc
polyketid
complex
genom
group
organ
make
difficult
identifi
target
genom
complic
use
inappropri
host
organ
clone
express
well
larg
size
gene
cluster
obstacl
manifold
sinc
spong
play
host
wide
divers
organ
bacteria
fungi
protist
etc
result
complex
commun
express
complex
metagenom
feasibl
simpl
express
system
e
coli
complex
express
system
need
achiev
success
case
spong
overcom
challeng
associ
success
implement
metagenom
approach
new
method
develop
test
recent
one
possibl
futur
direct
could
perform
sequenc
base
screen
order
identifi
enzym
shown
involv
synthesi
antivir
compound
strategi
success
develop
implic
known
polyketid
synthas
gene
effort
identifi
new
polyketid
recent
develop
phylogenet
approach
appli
studi
structur
function
biosynthet
enzym
well
isol
target
gene
cluster
metagenom
librari
also
screen
antivir
activ
tailor
methodolog
previous
use
identifi
naturalproduct
cluster
use
genom
sequenc
tag
gst
gst
part
gene
use
probe
screen
similar
gene
clonal
librari
clone
contain
gst
potenti
candid
screen
novel
naturalproduct
gene
cluster
approach
util
identifi
naturalproduct
cluster
literatur
regard
antivir
compound
spong
show
signific
marin
natur
product
drug
discoveri
develop
process
advanc
technolog
new
gener
potent
effect
antivir
agent
may
obtain
sourc
sequenc
base
screen
metagenom
clonal
librari
screen
use
gst
phylogenet
approach
could
provid
new
futur
dimens
search
antivir
natur
compound
spong
success
metagenom
coupl
heterolog
express
high
throughput
microbi
cultiv
techniqu
could
pave
way
commerci
product
compound
futur
greatli
facilit
analysi
commerci
